Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11


Direct visualization of heterogeneous extravascular distribution of trastuzumab in human epidermal growth factor receptor type 2 overexpressing xenografts.

Baker JH, Lindquist KE, Huxham LA, Kyle AH, Sy JT, Minchinton AI.

Clin Cancer Res. 2008 Apr 1;14(7):2171-9. doi: 10.1158/1078-0432.CCR-07-4465. Erratum in: Clin Cancer Res. 2008 May 1;14(9):2893.


Suppression of VEGF secretion and changes in glioblastoma multiforme microenvironment by inhibition of integrin-linked kinase (ILK).

Edwards LA, Woo J, Huxham LA, Verreault M, Dragowska WH, Chiu G, Rajput A, Kyle AH, Kalra J, Yapp D, Yan H, Minchinton AI, Huntsman D, Daynard T, Waterhouse DN, Thiessen B, Dedhar S, Bally MB.

Mol Cancer Ther. 2008 Jan;7(1):59-70. doi: 10.1158/1535-7163.MCT-07-0329.


Exploring vascular dysfunction caused by tirapazamine.

Huxham LA, Kyle AH, Baker JH, McNicol KL, Minchinton AI.

Microvasc Res. 2008 Mar;75(2):247-55. Epub 2007 Oct 11.


Limited tissue penetration of taxanes: a mechanism for resistance in solid tumors.

Kyle AH, Huxham LA, Yeoman DM, Minchinton AI.

Clin Cancer Res. 2007 May 1;13(9):2804-10.


Decreased levels of hypoxic cells in gefitinib treated ER+ HER-2 overexpressing MCF-7 breast cancer tumors are associated with hyperactivation of the mTOR pathway: therapeutic implications for combination therapy with rapamycin.

Dragowska WH, Verreault M, Yapp DT, Warburton C, Edwards L, Ramsay EC, Huxham LA, Minchinton AI, Gelmon K, Bally MB.

Breast Cancer Res Treat. 2007 Dec;106(3):319-31. Epub 2007 Mar 9.


Vascular-specific quantification in an in vivo Matrigel chamber angiogenesis assay.

Baker JH, Huxham LA, Kyle AH, Lam KK, Minchinton AI.

Microvasc Res. 2006 Mar;71(2):69-75. Epub 2006 Mar 20.


Tirapazamine causes vascular dysfunction in HCT-116 tumour xenografts.

Huxham LA, Kyle AH, Baker JH, McNicol KL, Minchinton AI.

Radiother Oncol. 2006 Feb;78(2):138-45. Epub 2006 Feb 7.


HER-2/neu overexpression increases the viable hypoxic cell population within solid tumors without causing changes in tumor vascularization.

Dragowska WH, Warburton C, Yapp DT, Minchinton AI, Hu Y, Waterhouse DN, Gelmon K, Skov K, Woo J, Masin D, Huxham LA, Kyle AH, Bally MB.

Mol Cancer Res. 2004 Nov;2(11):606-19.


Microregional effects of gemcitabine in HCT-116 xenografts.

Huxham LA, Kyle AH, Baker JH, Nykilchuk LK, Minchinton AI.

Cancer Res. 2004 Sep 15;64(18):6537-41.


Direct assessment of drug penetration into tissue using a novel application of three-dimensional cell culture.

Kyle AH, Huxham LA, Chiam AS, Sim DH, Minchinton AI.

Cancer Res. 2004 Sep 1;64(17):6304-9.


Tumor distribution of bromodeoxyuridine-labeled cells is strongly dose dependent.

Kyle AH, Huxham LA, Baker JH, Burston HE, Minchinton AI.

Cancer Res. 2003 Sep 15;63(18):5707-11.

Supplemental Content

Loading ...
Support Center